VBI Vaccines Inc. (VBIV) |
|
0.3247 0.012 (3.94%)
|
03-22 15:02 |
|
Open: |
0.31 |
Pre. Close: |
0.3124 |
|
High:
|
0.35 |
Low:
|
0.31 |
|
Volume:
|
421,301 |
Market Cap:
|
92(M) |
|
|
|
Technical analysis |
as of: 2023-03-22 2:51:49 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 0.51  One year: 0.66 |
| Support: |
Support1: 0.23 Support2: 0.19 |
| Resistance: |
Resistance1: 0.44 Resistance2: 0.56 |
| Pivot: |
0.36 |
| Moving Average: |
MA(5): 0.31 MA(20): 0.39
MA(100): 0.51 MA(250): 0.79 |
| MACD: |
MACD(12,26): -0.1  Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 22.1 %D(3): 12.3 |
| RSI: |
RSI(14): 33.1 |
| 52-week: |
High: 1.86 Low: 0.23 |
| Average Vol(K): |
3-Month: 933 (K) 10-Days: 998 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ VBIV ] has closed above bottom band by 30.8%. Bollinger Bands are 21.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.32 - 0.32 |
0.32 - 0.32 |
|
Low:
|
0.23 - 0.23 |
0.23 - 0.23 |
|
Close:
|
0.31 - 0.31 |
0.31 - 0.32 |
|
Company Description |
|
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the presentation of viruses to elicit a human immune system. Its lead eVLP program candidates include VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study; and VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial. The company also develops coronavirus vaccine candidates, such as VBI-2902 and VBI-2901. In addition, it engages in the development of vaccine platforms and products for licensing to pharmaceutical companies and biotechnology companies. It has collaboration and license agreements with Brii Biosciences Limited; and GlaxoSmithKline Biologicals S.A. The company also has a collaboration with the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. VBI Vaccines Inc. has collaboration with Coalition for Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts. |
Headline News |
Mon, 20 Mar 2023
VBI Vaccines Inc. (VBIV) Shares Down Despite Recent Market ... - The News Heater
Mon, 13 Mar 2023
VBI Vaccines, Inc. (VBIV) Reports Q4 Loss, Misses Revenue Estimates - Zacks Investment Research
Mon, 13 Mar 2023
North American Morning Briefing : Investors Digest -3- - Marketscreener.com
Mon, 13 Mar 2023
VBI Vaccines Reports Full Year 2022 Financial Results - VBI Vaccines
Mon, 06 Mar 2023
North American Morning Briefing : Focus This Week -3- - Marketscreener.com
Thu, 23 Feb 2023
VBI Vaccines to Discuss Progress in Hepatitis B Portfolio in Analyst ... - VBI Vaccines
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
258 (M) |
|
% Held by Insiders
|
1.9148e+008 (%) |
|
% Held by Institutions
|
0.5 (%) |
|
Shares Short
|
11,850 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-7.924e+007 |
|
EPS Est Next Qtl
|
-0.24 |
|
EPS Est This Year
|
-0.89 |
|
EPS Est Next Year
|
-1.01 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-9 |
|
Return on Assets (ttm)
|
339.4 |
|
Return on Equity (ttm)
|
-25.7 |
|
Qtrly Rev. Growth
|
870000 |
|
Gross Profit (p.s.)
|
103.86 |
|
Sales Per Share
|
-48.13 |
|
EBITDA (p.s.)
|
-5.36508e+006 |
|
Qtrly Earnings Growth
|
-0.3 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-73 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.01 |
|
Price to Cash Flow
|
0.89 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
1.291e+007 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2012-12-27 |
|
Ex-Dividend Date
|
2012-02-04 |
|
Your Ad Here
|
|
